Literature DB >> 29080421

Molecular mechanism of Gd@C82(OH)22 increasing collagen expression: Implication for encaging tumor.

Jing Liu1, Seung-Gu Kang2, Peng Wang1, Yue Wang1, Xiaonan Lv1, Ying Liu1, Fei Wang3, Zonglin Gu4, Zaixing Yang4, Jeffrey K Weber2, Ning Tao5, Zhihai Qin5, Qing Miao6, Chunying Chen7, Ruhong Zhou8, Yuliang Zhao9.   

Abstract

Gadolinium-containing fullerenol Gd@C82(OH)22 has demonstrated low-toxicity and highly therapeutic efficacy in inhibiting tumor growth and metastasis through new strategy of encaging cancer, however, little is known about the mechanisms how this nanoparticle regulates fibroblast cells to prison (instead of poison) cancer cells. Here, we report that Gd@C82(OH)22 promote the binding activity of tumor necrosis factor (TNFα) to tumor necrosis factor receptors 2 (TNFR2), activate TNFR2/p38 MAPK signaling pathway to increase cellular collagen expression in fibrosarcoma cells and human primary lung cancer associated fibroblasts isolated from patients. We also employ molecular dynamics simulations to study the atomic-scale mechanisms that dictate how Gd@C82(OH)22 mediates interactions between TNFα and TNFRs. Our data suggest that Gd@C82(OH)22 might enhance the association between TNFα and TNFR2 through a "bridge-like" mode of interaction; by contrast, the fullerenol appears to inhibit TNFα-TNFR1 association by binding to two of the receptor's cysteine-rich domains. In concert, our results uncover a sequential, systemic process by which Gd@C82(OH)22 acts to prison tumor cells, providing new insights into principles of designs of cancer therapeutics.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Caging cancer cells; Cancer therapeutics; Fibrosarcoma cells; Gd-metallofullerenol; Molecular dynamics; TNF receptors

Mesh:

Substances:

Year:  2017        PMID: 29080421     DOI: 10.1016/j.biomaterials.2017.10.027

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  7 in total

Review 1.  The Roles of TNFR2 Signaling in Cancer Cells and the Tumor Microenvironment and the Potency of TNFR2 Targeted Therapy.

Authors:  Hiroyuki Takahashi; Gumpei Yoshimatsu; Denise Louise Faustman
Journal:  Cells       Date:  2022-06-17       Impact factor: 7.666

2.  Endohedral Gd-Containing Fullerenol: Toxicity, Antioxidant Activity, and Regulation of Reactive Oxygen Species in Cellular and Enzymatic Systems.

Authors:  Ekaterina S Sushko; Natalia G Vnukova; Grigoriy N Churilov; Nadezhda S Kudryasheva
Journal:  Int J Mol Sci       Date:  2022-05-05       Impact factor: 6.208

3.  Amphiphilic Aminated Derivatives of [60]Fullerene as Potent Inhibitors of Tumor Growth and Metastasis.

Authors:  Jiawei Huo; Jie Li; Yang Liu; Libin Yang; Xinran Cao; Chong Zhao; Yicheng Lu; Wei Zhou; Shumu Li; Jianan Liu; Jiao Li; Xing Li; Jing Wan; Rui Wen; Mingming Zhen; Chunru Wang; Chunli Bai
Journal:  Adv Sci (Weinh)       Date:  2022-08-28       Impact factor: 17.521

Review 4.  TNF Receptor 2 Makes Tumor Necrosis Factor a Friend of Tumors.

Authors:  Yuqiao Sheng; Feng Li; Zhihai Qin
Journal:  Front Immunol       Date:  2018-05-28       Impact factor: 7.561

Review 5.  The role of collagen in cancer: from bench to bedside.

Authors:  Shuaishuai Xu; Huaxiang Xu; Wenquan Wang; Shuo Li; Hao Li; Tianjiao Li; Wuhu Zhang; Xianjun Yu; Liang Liu
Journal:  J Transl Med       Date:  2019-09-14       Impact factor: 5.531

Review 6.  Antitumor Activity and Potential Mechanism of Novel Fullerene Derivative Nanoparticles.

Authors:  Lianjie Ye; Larwubah Kollie; Xing Liu; Wei Guo; Xiangxian Ying; Jun Zhu; Shengjie Yang; Meilan Yu
Journal:  Molecules       Date:  2021-05-28       Impact factor: 4.411

7.  The Molecular Mechanism of Human Voltage-Dependent Anion Channel 1 Blockade by the Metallofullerenol Gd@C82(OH)22: An In Silico Study.

Authors:  Xiuxiu Wang; Nan Yang; Juan Su; Chenchen Wu; Shengtang Liu; Lei Chang; Leigh D Plant; Xuanyu Meng
Journal:  Biomolecules       Date:  2022-01-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.